SmurfVA's Random Picks

[Ned Serious]

RGDX News: Announces Contracts With Six New Provider Networks

link: http://boardvote.com/symbol/RGDX/communique/601688


LOS ANGELES, April 3, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has signed agreements with six additional health plans across 10 states bringing the Company's total national contracted membership to more than 174 million lives.

The new agreements include additional Blue Cross Blue Shield contracts in Arizona, Iowa, South Dakota, Pennsylvania, Delaware, and West Virginia. The Company also signed new agreements with an Independent Physician Association (covering two states) in the North West region and a Commercial Health Plan (covering two states) in the North East region of the United States.

These partnerships mark a further step forward in Response Genetics' growing managed care contracting program. With these agreements, Response Genetics is now in-network with a total of thirteen Blue Cross Blue Shield health plans, which brings the total number of "Blues" subscribers with direct access to Response Genetics to approximately 23 million. Among Response Genetics' other Blue Cross Blue Shield contracts are Blue Cross and Blue Shield of Illinois, Blue Shield of California and CareFirst BlueCross BlueShield (Maryland, Washington, DC and Northern Virginia).

In addition to its recently launched proprietary ResponseDX: Tissue of Origin™ diagnostic test, Response Genetics' molecular testing primarily focuses on therapy-selection for patients with lung, colon, gastric, melanoma, and thyroid cancers. Response Genetics' menu of genomic assays provides treating physicians actionable information on a patient's tumor by predicting which course of therapy will work best for that patient. In this way, Response Genetics' participation with these Blues plans should improve plan members' access to individually-tailored medicine.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.